Media playback is unsupported on your device

GlaxoSmithKline and Novartis deal 'shows focus'

24 April 2014 Last updated at 02:34 BST

Earlier this week, two giants of the pharmaceutical industry Novartis and GlaxoSmithKline (GSK) struck a multi-billion-dollar deal to join forces and reshape their businesses.

The deal involves swapping assets and combining their consumer health units.

Novartis will acquire GSK's cancer drugs business for $16bn (£9.5bn) and sell its vaccines division, excluding the flu unit, to GSK for $7.1bn.

It's the latest in a slew of deals in the pharmaceuticals industry.

But why now, and what does it mean for Asia? Keith Lostaglio of consultants A T Kearney tells the BBC what is behind the deal.

Watch more reports on Asia Business Report's website.

Copyright © 2015 BBC. The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.